Plus Therapeutics Delays Quarterly Report Filing

Plus Therapeutics ( (PSTV) ) has released a notification of late filing.

Plus Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The delay is primarily due to the need for additional time to finalize the accounting treatment of common stock purchase warrants issued in a recent securities purchase agreement. The company expects to file the report within five calendar days following the prescribed due date. Plus Therapeutics anticipates recognizing a liability related to these warrants, which may lead to a decrease in stockholders’ equity as of March 31, 2025. The company is actively working on compliance and the notification was signed by President and CEO, Marc H. Hedrick, M.D.

The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Spark’s Take on PSTV Stock

According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.

Plus Therapeutics is facing significant financial challenges with consistent losses and negative equity, which are major risks. While there are positive future growth prospects from clinical trials and strategic financing efforts, the stock remains risky due to its current financial instability.

To see Spark’s full report on PSTV stock, click here.

More about Plus Therapeutics

Average Trading Volume: 17,471,401

Technical Sentiment Signal: Strong Sell

Current Market Cap: $11.87M

Learn more about PSTV stock on TipRanks’ Stock Analysis page.